Search This Blog

Sunday, June 23, 2013

Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function (NYSE:LLY)

Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.